EZH2 and neoplasm: EED226impaired proliferation in EZH2 orthosteric inhibitor-resistant cancercells and also achieved complete tumor regression in a mouse model.Of note, when 35 and the orthosteric EZH2 inhibitor EI1were combined, synergistic antiproliferative effects were observedhence providing a more efficient anticancer strategy by combiningtwo PRC2 modulators with two different mechanisms of action.